The indictment alleges that the Las Vegas businessman recruited physicians, podiatrists, and other practitioners to use Protectus-supplied wound-care products whose substantial government reimbursements allegedly supported provider profit shares, sales commissions, and misleading acquisition-cost disclosures.
WASHINGTON, DC — Federal prosecutors in the Northern District of Texas accuse Michael McMillan of building a nationwide recruitment system that allegedly steered physicians, podiatrists, and other medical providers toward skin-substitute products capable of generating exceptionally valuable reimbursements from taxpayer-funded health programs.
McMillan, a 55-year-old Las Vegas resident who controlled Protectus LLC and several related companies, faces a nine-count indictment alleging two conspiracies and seven monetary transactions involving property that authorities contend was derived from a sprawling health care fraud and kickback scheme.
Prosecutors say Medicare, TRICARE, and CHAMPVA paid approximately $268 million on skin-substitute claims connected to the challenged arrangements, while Protectus allegedly collected about $174 million and allowed participating providers to retain approximately $94 million through margins the government characterizes as illegal remuneration.
Every assertion remains an allegation, McMillan is presumed innocent unless proven guilty beyond a reasonable doubt, and neither the scale of the claimed reimbursements nor the government’s seizure of valuable property establishes criminal liability before evidence is tested through the judicial process.
Recruitment Was Central to the Alleged Business Model
The prosecution’s theory begins with recruitment rather than bedside treatment, portraying McMillan as the organizer of a commercial network whose value depended upon persuading licensed practitioners to select Protectus products, apply them to patients, submit claims, and share the resulting government payments.
According to the federal indictment against Michael McMillan, McMillan and his companies recruited physicians, podiatrists, and other providers from approximately May 2019 through at least February 2026, offering financial terms that allegedly converted product selection into a dependable profit opportunity.
The filing identifies five medical providers by letters rather than names, describing a physician in Arlington, Texas; podiatrists in Santa Monica, California, McKinney, Texas, and Payson, Utah, and a nurse practitioner residing in Dallas, thereby illustrating the alleged network’s interstate reach.
The indictment also identifies four sales representatives anonymously, listing locations in Trophy Club and Dallas, Texas; La Mirada, California; and Lehi, Utah, reinforcing the government’s contention that recruitment was organized through geographically dispersed commercial relationships rather than one medical office.
Protectus was not a single isolated company under the indictment’s description, because prosecutors grouped six Nevada entities controlled by McMillan, including Protectus Technologies, Protectus Consulting, Prestige Medical Consultants, Velare Wound Care, and Amnio ReGen Solutions, under the collective Protectus label.
That constellation allegedly allowed McMillan to offer skin-substitute inventory, provide billing assistance, issue reimbursement-based invoices, calculate provider shares, compensate recruiters, and retain substantial proceeds, although the defense may dispute whether the entities performed lawful and distinct commercial functions misunderstood by investigators.
Products, Manufacturers, and Reimbursement Incentives
Skin substitutes, also called cellular or tissue-based products, allografts, or wound grafts, are applied over qualifying open wounds to encourage closure or tissue growth, and they can deliver legitimate clinical value when medical necessity, documentation, sizing, application, and follow-up requirements are satisfied.
Government reimbursement has historically been calculated partly through product-specific pricing and the number of square centimeters applied, meaning selecting a highly reimbursed product and a larger graft size can dramatically increase the payment associated with a single treatment encounter.
The indictment says Protectus offered various products and encouraged providers to use its companies’ skin substitutes, but it does not publicly name particular manufacturers or brands, and no manufacturer should be portrayed as accused merely because its product may have moved through an investigated distribution channel.
That omission is important because the phrase “manufacturer-linked product” can describe ordinary supply-chain provenance without implying criminal participation, while the government’s charged theory concerns McMillan’s alleged recruitment, pricing, billing, payment, and commission practices rather than an announced prosecution of an identified manufacturer.
Nevertheless, product selection sits at the center of the alleged economics, because a reimbursement formula tied to a product’s assigned price and applied area can create far larger margins than conventional wound dressings, especially when the provider pays nothing before the claim is adjudicated.
Prosecutors will therefore need to demonstrate how particular products entered the network, what Protectus actually paid to acquire them, what providers were told about reimbursement, how clinical choices were made, and whether commercial incentives improperly influenced federally reimbursable orders.
The defense can answer with evidence concerning genuine product delivery, medical value, independent clinical judgment, market pricing, contract terms, compliance advice, and billing guidance, because selling an expensive medical product or earning a substantial lawful margin does not automatically constitute fraud or a kickback.
No Upfront Cost Allegedly Removed Provider Risk
The recruitment pitch allegedly began by removing a major practical obstacle for medical practices: Protectus supplied skin substitutes without requiring providers to pay upfront, allowing clinicians to use expensive inventory before knowing whether Medicare or another government program would approve reimbursement.
If a government program denied a claim, prosecutors say Protectus did not charge the provider for the associated product, leaving the practice with no product-acquisition loss and transferring the ordinary reimbursement risk back to the distributor-controlled arrangement.
When the program paid, however, Protectus allegedly waited until the provider received reimbursement and then issued an invoice calculated as a percentage of that payment, usually between 60 percent and 70 percent, rather than charging a fixed amount established independently of the claim result.
The provider allegedly retained the remaining 30 percent to 40 percent, producing thousands of dollars in profit from each reimbursed skin-substitute claim and creating what prosecutors describe as remuneration intended to influence ordering decisions financed by federal health care programs.
This structure allegedly gave the recruitment offer unusual persuasive power because a participating practitioner could receive products without initial capital, avoid payment after denial, get help with billing, and keep a substantial share whenever the claim generated government reimbursement.
The defense may contend that contingent credit, delayed invoicing, discounting, replacement arrangements, or risk-sharing can have legitimate commercial explanations, while prosecutors must prove that the actual purpose and operation of these terms crossed from aggressive business development into knowing criminal inducement.
A March 2024 Meeting Illustrates the Alleged Pitch
One particularly detailed allegation concerns a March 2024 meeting during which McMillan allegedly told an unidentified Texas podiatrist that Protectus offered providers an average rebate of 35 percent for using skin-substitute products supplied through the network.
Prosecutors say McMillan illustrated the opportunity with a monthly example, explaining that if the podiatrist billed and collected $180,000 from Medicare for skin-substitute claims, the practitioner would retain 35 percent, or approximately $63,000, from those payments.
During the same meeting, the indictment alleges, McMillan said he reviewed every Medicare claim to ensure that Protectus products were billed at a higher price than providers actually paid, an assertion likely to become central when the parties litigate knowledge and intent.
Protectus allegedly supplied that podiatrist with 12 skin-substitute products at no upfront cost in March or April 2024, turning the presentation into a working relationship that prosecutors later traced through reimbursement and invoice records.
After the provider reported that Medicare paid $9,024 on one claim and denied another, a Protectus employee allegedly explained that the paid claim would generate an invoice, and the company would help resolve the denial once it received the necessary information.
The employee subsequently issued an invoice for $5,865.60, representing 65 percent of the reported reimbursement, while the denied product apparently generated no immediate charge, closely matching the contingent-payment structure that prosecutors describe throughout the broader scheme.
Those allegations offer jurors a concrete transaction rather than only aggregate figures, but the defense can examine the complete meeting context, governing contract, product acquisition records, claim documentation, and communications before arguing whether the example demonstrates unlawful inducement or lawful negotiated pricing.
Billing Assistance and the Box 19 Allegation
Protectus employees allegedly submitted claims for participating providers or helped them prepare claims, giving the distributor access to billing details that prosecutors say were essential for preserving the reimbursement-based pricing model and calculating what each provider and representative would receive.
The indictment places particular emphasis on Box 19 of the Medicare claim form, alleging that providers were required to disclose the actual product price after discounts, rebates, refunds, and adjustments rather than reporting a larger figure disconnected from their ultimate economic obligation.
Prosecutors contend that McMillan and Protectus submitted inflated acquisition prices or counseled providers to do so, thereby presenting government programs with a misleading cost figure while internal agreements allegedly guaranteed that practitioners would surrender only 60 percent to 70 percent of reimbursement.
In the May 2024 transaction, a Protectus employee allegedly noticed that Box 19 information was missing from the podiatrist’s claim and directed the provider to resubmit using pricing information in a company spreadsheet, which an episode investigator may use to argue operational control.
The legal significance will depend on the governing reimbursement instructions, what information the box required for each program and claim type, whether the figure was materially inaccurate, who controlled submission, and whether McMillan knowingly made any false representation that influenced payment.
Ambiguous billing guidance, administrative errors, or reasonable reliance on specialists can undermine a criminal-intent theory, but documented directions to use a price known to differ from the provider’s actual obligation could give prosecutors evidence beyond a routine coding disagreement.
Invoices Allegedly Recorded the Provider Split
The indictment describes an October 2022 invoice showing that an unidentified Utah podiatrist collected $53,625.60, retained $16,087.68, and owed Protectus $37,537.92, numbers that precisely correspond to a 30 percent provider share and a 70 percent distributor share.
Another allegation concerns a July 2023 invoice sent to the Arlington physician, whose employee reportedly complained that the document reflected a 35 percent provider profit even though a newer contract promised 40 percent, prompting McMillan to direct that the calculation be corrected.
That exchange may be especially consequential because prosecutors can characterize it as explicit recognition that provider compensation was expressed as a profit percentage tied to collected reimbursement, while the defense may argue that the language merely summarized a lawful net-price discount.
A December 2023 email described in the filing shows another provider requesting a refund from Protectus after returning claim payments to Medicare for rebilling under a different company, and Protectus allegedly processed the requested refund through its invoicing system.
For prosecutors, these records may show that product charges rose, fell, or disappeared with claim outcomes rather than ordinary wholesale pricing, while the defense can argue they reflect responsive accounting, corrected billing, and a willingness to return money when reimbursement changed.
Sales Representatives Allegedly Expanded the Network
McMillan allegedly hired representatives specifically to recruit medical providers, directed them to explain the profit-sharing structure, and paid them only after recruited practices received government reimbursement and remitted the agreed percentage to Protectus, creating a second contingency within the alleged scheme.
Representative compensation was allegedly calculated as a percentage of money Protectus received from recruited providers, meaning a salesperson’s earnings increased when those practitioners generated more reimbursed skin-substitute claims and successfully transferred larger invoice payments back to the distributor.
Prosecutors estimate that Protectus paid approximately $27 million to sales representatives, characterizing those commissions as illegal kickbacks intended to induce medical referrals, although the legal analysis must distinguish compensation for legitimate sales activity from payments unlawfully connected to federally reimbursable ordering decisions.
One November 2022 communication allegedly involved a representative disputing a commission report that omitted $6,446.55 connected to provider reimbursements, while a company employee responded that commissions could be paid only after an office confirmed that insurance had paid the underlying claims.
Another monthly report allegedly awarded a Utah representative more than $120,000, including compensation linked to the provider invoice dividing approximately $53,625 in collections, giving investigators a documentary path from government reimbursement through provider payment and onward to recruiter compensation.
The recruitment structure consequently forms a three-level financial chain in the government’s narrative: federal programs paid providers, providers retained an alleged inducement and paid Protectus, and Protectus then compensated representatives according to business generated by the practitioners they recruited.
The Aggregate Economics Behind the Charges
Across the alleged scheme, government programs paid approximately $268 million, providers received about $94 million through challenged retained margins, Protectus collected roughly $174 million, and representatives received approximately $27 million from the distributor’s receipts, according to the indictment’s aggregate calculations.
Those figures should not be added as though they represent separate government losses, because the provider margin, Protectus receipts, and representative compensation describe different allocations or downstream movements within the broader reimbursement stream prosecutors identified.
The indictment further alleges that McMillan used proceeds to buy houses, condominiums, luxury vehicles, and a private jet, while seven transaction counts identify specific payments tied to real estate, a Lamborghini, a Cadillac Escalade, and a Cessna Citation aircraft.
Authorities reported seizing assets valued at approximately $35 million, but pretrial seizure preserves disputed property and does not prove criminal origin, leaving McMillan and potentially affecting third parties able to challenge tracing, valuation, ownership, probable cause, and forfeiture theories.
What the Nine Federal Counts Actually Allege
Count One charges conspiracy to commit health care fraud under Title 18, Section 1349, alleging an agreement to submit materially false claims and claims induced by kickbacks, rather than charging every questioned treatment encounter as a separate substantive health care fraud offense.
Count Two charges a conspiracy under Title 18, Section 371 to defraud the United States and pay kickbacks connected to a federal health care program, focusing upon alleged efforts to impair Medicare oversight while inducing orders through checks, wires, discounts, and other remuneration.
Counts Three through Nine charge monetary transactions in criminally derived property under Title 18, Section 1957, requiring prosecutors to trace specified transactions exceeding $10,000 to proceeds derived from the alleged health care and kickback conspiracies while proving the necessary knowledge.
The distinction matters because prosecutors must establish an agreement, McMillan’s knowing and willful participation, material deception, unlawful inducement, and the criminal source of particular funds, while the defense can contest every element without proving an alternative explanation beyond a reasonable doubt.
Why the Northern District of Texas Has Jurisdiction
Although McMillan resided in Nevada and the alleged network reached multiple states, prosecutors placed the case in Dallas because providers, representatives, communications, bank transfers, claim activity, and other overt acts allegedly occurred within the Northern District of Texas during the charged conspiracies.
The indictment describes an Arlington physician, a Dallas nurse practitioner, a McKinney podiatrist, and representatives in Trophy Club and Dallas, while specific checks, deposits, invoices, emails, and meetings allegedly tied key parts of the operation to North Texas.
Venue may still receive careful defense scrutiny in a multi-state prosecution, especially for individual financial counts, but conspiracies can be prosecuted where qualifying agreements or overt acts occurred when statutory and constitutional requirements are otherwise satisfied.
A Major Case Within the 2026 National Takedown
The Justice Department announced the McMillan prosecution on June 23, 2026, during its National Health Care Fraud Takedown, which charged 455 defendants across 56 federal districts and alleged more than $6.5 billion in false claims involving federal and state programs.
North Texas authorities announced seven cases involving 13 defendants and more than $365 million in alleged fraudulent billing, placing McMillan’s approximately $268 million matter at the center of the district’s coordinated enforcement presentation by claimed payment value.
An NBC 5 Dallas-Fort Worth report on the enforcement action described allegations involving elderly beneficiaries, military families, wound-care products, laboratory testing, hospice services, brain-related testing, COVID-19 kits, and durable medical equipment across the regional prosecutions.
Federal officials credited investigators from the Federal Bureau of Investigation’s Dallas office, the Department of Health and Human Services inspector general, the Defense Criminal Investigative Service, and the Department of Veterans Affairs inspector general with investigating McMillan’s case.
That agency combination reflects the three principal programs identified as payers, since Medicare serves older and disabled beneficiaries, TRICARE supports military communities, and CHAMPVA shares qualifying health costs for certain spouses, children, survivors, and caregivers connected to veterans.
Data Analytics Can Reveal Recruitment Patterns
Skin-substitute investigations increasingly rely on claims analytics that can identify sudden billing growth, unusually expensive product preferences, repeated applications, concentrated distributor relationships, large per-patient totals, geographic expansion, and providers whose patterns change immediately after contact with a particular representative.
Investigators can map each recruited practice against product codes, square centimeters, reimbursement dates, invoice percentages, denial outcomes, sales commissions, and bank transfers, then compare that chronology with emails or meetings explaining why the provider adopted the distributor’s products.
Statistics alone cannot establish criminal intent, because difficult patient populations, clinical specialization, new treatment programs, regional referrals, lawful discounts, or rapid but legitimate growth may create substantial outliers without proving that anyone knowingly joined a fraudulent agreement.
Decisive evidence will therefore turn on whether data patterns align with contracts, communications, spreadsheets, invoices, witness testimony, acquisition records, and claim instructions showing a deliberate inducement system, or instead support legitimate explanations for commercially unusual but lawful conduct.
Compliance Lessons for Manufacturers and Distributors
Manufacturers should know how products move through every distribution layer, because even when they are not accused of wrongdoing, poorly supervised downstream marketing can attach a brand to investigations involving aggressive reimbursement promises, questionable discounts, compromised documentation, or medically unsupported utilization.
Distributors should set product prices based on documented commercial factors rather than a provider’s eventual government reimbursement, and avoid arrangements that eliminate every downside, guarantee unusually large retained margins, or compensate recruiters based on the value or volume of federally reimbursed orders.
Sales materials should emphasize clinical evidence, approved uses, coverage criteria, product handling, and accurate documentation, not present a treatment choice as an arithmetic opportunity to predict monthly profits from taxpayer-funded claims.
Commission plans require specialized review whenever representatives recruit federal-program providers, because percentage compensation tied to collected reimbursement can create significant Anti-Kickback Statute exposure even when contracts describe the transfers as commissions, consulting payments, marketing fees, rebates, or ordinary sales incentives.
Compliance Lessons for Physicians and Podiatrists
Physicians, podiatrists, and nurse practitioners remain responsible for independently determining medical necessity, confirming coverage, documenting wound history and conservative treatment, measuring product use and waste, and ensuring that claim information accurately reflects the full economics of acquisition.
A supplier’s promise to handle billing does not transfer all legal responsibility away from the enrolled provider, particularly when the clinician knows that a claim reports one acquisition figure while a private invoice, rebate, refund, or contingent agreement produces a materially different net cost.
Practices should preserve contracts, invoices, rebate calculations, denial correspondence, claim spreadsheets, clinical notes, product-shipping records, and compliance advice, because those materials can later demonstrate either appropriate lawful conduct or warning signs that financial incentives displaced independent judgment.
When a distributor offers inventory without upfront payment and waives charges after denial, counsel should examine whether the arrangement provides impermissible remuneration, whether discounts are properly disclosed, and whether any applicable exception or safe harbor genuinely fits the transaction as operated.
Patients and Taxpayers Remain the Essential Stakeholders
Chronic wounds can threaten mobility, independence, and life, meaning patients deserve product selections based upon clinical need and credible evidence rather than the financial return available to a distributor, representative, or practitioner after a government program processes a claim.
Taxpayers and beneficiaries also bear indirect costs when inflated or improperly induced payments drain public funds, provoke restrictive coverage reforms, overwhelm honest providers with audits, and reduce confidence in treatments that may offer real value when used appropriately.
Fairness nevertheless requires separating systemic concern from individual guilt, because a troubling payment model, extraordinary billing total, or luxury purchase cannot substitute for admissible evidence establishing that McMillan knowingly entered each charged conspiracy and conducted each alleged criminally derived transaction.
Responding to an Indictment Without Obstructing Justice
Executives and medical practices associated with a major prosecution should coordinate factual communications with qualified counsel, preserve all potentially relevant records, correct demonstrable public errors, and avoid statements that could influence witnesses, conceal evidence, retaliate against participants, or misrepresent unresolved allegations as established facts.
Amicus International Consulting’s crisis public-relations resources emphasize early assessment, disciplined messaging, and organized response planning, principles that remain lawful only when communication is accurate, transparent about procedural status, and entirely separated from any effort to impede investigators or courts.
Its reputation-rebuilding guidance similarly underscores sustained, credible information rather than instant erasure, an especially relevant distinction when search results preserve the government’s allegations long before discovery, motions, expert disputes, negotiations, trial, or final adjudication establish what occurred.
What Happens Next in the Michael McMillan Case
The case will proceed through arraignment, discovery, pretrial motions, expert review, and possible negotiations, with prosecutors and defense lawyers expected to examine years of claims, product records, bank transactions, invoices, communications, contracts, and reimbursement rules across several government programs.
Potential disputes may address warrant evidence, asset restraints, venue, claim sampling, acquisition-cost guidance, expert methodology, provider independence, commission calculations, safe-harbor arguments, loss estimates, and whether particular records demonstrate knowing deception or merely aggressive commercial practices within a complicated reimbursement environment.
Cooperating providers or representatives could become important witnesses, but jurors would have to evaluate their credibility, incentives, plea or immunity arrangements, financial exposure, and consistency with contemporaneous documents rather than accepting testimony solely because it supports either side’s narrative.
McMillan may seek dismissal of selected counts, suppression of evidence, release of restrained property, a negotiated resolution, or trial, and no responsible account can predict the outcome before both sides obtain discovery and the court decides disputed legal and evidentiary questions.
For now, the Northern District of Texas indictment presents provider recruitment as the engine of an alleged skin-substitute kickback scheme, showing how product choice, reimbursement, delayed invoicing, profit sharing, billing assistance, and sales commissions can combine into a major federal prosecution.
The filing also sends a broader warning that manufacturers, distributors, representatives, physicians, and podiatrists must evaluate the real economic operation of wound-care agreements, because labels such as discount, rebate, commission, or credit cannot protect remuneration intended to generate federally reimbursed orders.
Most importantly, the accusations against Michael McMillan and every unnamed participant remain unproven; the United States bears the complete burden of proof, and the presumption of innocence continues unless a valid guilty plea or unanimous jury verdict establishes criminal responsibility under governing law.
